Tollys

General Information

Company Name

Tollys

Founded Year

2015

Location (Offices)

France +1

Founders / Decision Makers

Number of Employees

Industries

Biopharma, Biotechnology, Pharmaceutical

Funding Stage

Series A

Social Media

Tollys - Company Profile

Tollys: Transforming Immuno-Oncology

Tollys, a biopharmaceutical company based in France, is pioneering specific TLR3 agonists in the field of immuno-oncology. Founded in 2015 by senior scientists from the European Cancer Research Center of Lyon and the Centre Léon Bérard, Tollys' groundbreaking research has uncovered the potential of TLR3 agonists to induce direct and immunogenic tumor cell death while activating antigen presenting cells and reshaping the tumoral micro-environment.

Their lead candidate, TL-532, has shown promising efficacy in preclinical models, demonstrating an ability to induce anti-tumor response and prevent recurrences, especially when combined with immune checkpoint inhibitors. With its plans to enter clinical trials in 2021 for Non Muscle Invasive Bladder cancer (NMIBC), Tollys is targeting a high medical need indication with a potential for accelerated market approval.

The company's recent €2.30M Series A investment received on 26th May 2020 from Investisseurs privés underscores the growing interest and confidence in Tollys' innovative approach to immuno-oncology, presenting a significant opportunity for investors seeking to support cutting-edge advancements in the biopharmaceutical and biotechnology sectors.

Taxonomy: Immuno-oncology, TLR3 agonists, Cancer research, Biopharmaceutical company, TL-532, Clinical trials, Non Muscle Invasive Bladder cancer, Immune checkpoint inhibitors, Innate immunity, TLR3 receptor, Biological modulation, Synthetic dsRNA, Tumor micro-environment, Antigen presenting cells, Clinical efficacy